Evidence map›Paper›PMID 26849514›Full record

ArticleNature biotechnology2016

Precision and robustness of 2D-NMR for structure assessment of filgrastim biosimilars.

Houman Ghasriani, Derek J Hodgson, Robert G Brinson, Ian McEwen, Lucinda F Buhse, Steven Kozlowski, John P Marino, Yves Aubin, David A Keire

Abstract readLetter
In one paragraph

Article in Nature biotechnology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed.

  1. Article
  2. Article
  3. Electrochemistry as a Tool for Redox-Based Bio-Information Processing.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Comparability of Biologics: Global Principles, Evidentiary Consistency and Unrealized Reliance.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2021
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Houman GhasrianiUS Food and Drug Administration, Center for Drug Evaluation and Research, Division of Pharmaceutical Analysis, St. Louis, Missouri, USA.
Derek J HodgsonCentre for Biologics Evaluation, Biologics and Genetic Therapies Directorate, Health Canada, Ottawa, Ontario, Canada.
Robert G BrinsonInstitute for Bioscience and Biotechnology Research, National Institute of Standards and Technology, Rockville, Maryland, USA.
Ian McEwenMedical Products Agency of Sweden, Uppsala, Sweden.
Lucinda F BuhseUS Food and Drug Administration, Center for Drug Evaluation and Research, Division of Pharmaceutical Analysis, St. Louis, Missouri, USA.
Steven KozlowskiUS Food and Drug Administration, Center for Drug Evaluation and Research, Office of Biotechnology Products, Silver Spring, Maryland, USA.
John P MarinoInstitute for Bioscience and Biotechnology Research, National Institute of Standards and Technology, Rockville, Maryland, USA.
Yves AubinCentre for Biologics Evaluation, Biologics and Genetic Therapies Directorate, Health Canada, Ottawa, Ontario, Canada.
David A KeireUS Food and Drug Administration, Center for Drug Evaluation and Research, Division of Pharmaceutical Analysis, St. Louis, Missouri, USA.

Funding

Intramural NIST DOC 9999-NIST
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Biosimilar PharmaceuticalsFilgrastimChemistry, PharmaceuticalNuclear Magnetic Resonance, BiomolecularReproducibility of ResultsBiosimilar PharmaceuticalsFilgrastim

Identifiers

PMID26849514
PMCPMC5218811

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.